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Hutchinson-Gilford progeria syndrome (HGPS) is an 
autosomal dominant disease characterized by early onset 
of several pathologies associated with old age, including 
arteriosclerosis, strokes, loss of subcutaneous fat, and 
alopecia. However, patients with HGPS do not develop 
other pathologies associated with aging (such as neuro-
degeneration), suggesting that the pathophysiology is 
limited to certain cell lineages, particularly those of 
mesen  chymal origin [1]. Th   e disease is caused by a muta-
tion in the LMNA gene encoding the intermediate 
ﬁ  lament protein lamin A/C, which is critical for nuclear 
architecture of diﬀ  erentiated cells. Th  e lamins also are 
important for genome organization, tethering chromatin 
to the nuclear envelope to help dictate domains of 
heterochromatin. Th   e HGPS mutation activates a cryptic 
splice donor site, resulting in synthesis of a dominant 
negative, incompletely processed form of lamin A, 
termed progerin [2]. Th  e expression of progerin alters 
nuclear structure and heterochromatin, aﬀ  ecting  cell 
cycle progression, gene expression, and genomic stability. 
Progerin is hypothesized to promote sequestration of 
DNA repair and replication proteins, resulting in a more 
frequent stalling of replication forks and thereby 
replication-dependent double-strand breaks [3]. Progerin 
is farnesylated on its C-terminus, leading to concen-
tration of the truncated protein at the nuclear periphery 
and leading to rigidity of the normally dynamic nuclear 
lamina [4], the structure meshwork lining the nuclear 
membrane. Currently, inhibitors of farnesylation are the 
only available strategy for treating HGPS but are 
incompletely eﬀ  ective because they are nonspeciﬁ  c.
Interestingly, the cryptic splice site in LMNA is 
sporadically used in cells from normal individuals, 
leading to a low-level expression of progerin [5]. Further-
more, ﬁ  broblasts from individuals who are more than 
80 years old show nuclear abnormalities and changes in 
heterochromatin markers typical of cells from adolescent 
patients with HGPS. Th  us, progerin may contribute to 
both accelerated and normal aging. However, establishing 
a direct causal role for progerin (or anything else) in 
aging is particularly challenging.
Progerin also leads to activation of NOTCH, a crucial 
regulator of stem cell diﬀ  erentiation [6]. Th  us,  consti  tu-
tive expression of progerin in human mesenchymal stem 
cells (MSCs) induces aberrant expression of diﬀ  eren-
tiation markers [6]. Th   is supports the notion that HGPS 
is caused by dysfunction of adult stem cell populations 
(in particular mesenchymal progenitors), resulting in 
stem cell exhaustion. But this raises the question of 
whether patients with HGPS will ever be amenable to 
autologous stem cell therapy to delay their degenerative 
symptoms.
Th  e recent development of technology to reprogram 
somatic diﬀ  erentiated cells into induced pluripotent stem 
cells (iPSCs) allows the generation of stem cells from 
virtually anyone, including patients with rare genetic 
diseases that lead to premature stem cell exhaustion [7]. 
iPSCs, which pro  lifer  ate extensively in culture, can be 
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diﬀ  erentiating cells into speciﬁ  c lineages. For example, 
motor neurons diﬀ  erentiated from iPSCs produced from 
patients with spinal muscular atrophy are smaller, have 
impaired pre-synaptic maturation, and degenerate more 
rapidly than motor neurons produced from normal iPSCs 
[8]. Disease-speciﬁ  c iPSCs are ideal for screening drugs 
that improve production of fully functional diﬀ  erentiated 
cells. In addition, the iPSCs can be forcibly diﬀ  erentiated 
into speciﬁ  c types of progenitor cells, such as MSCs, of 
therapeutic value.
To study the biology of HGPS, two groups [9,10] 
recently generated iPSCs from ﬁ  broblasts of patients with 
HGPS by transduction with retroviral vectors encoding 
OCT4, SOX2, KLF4, and c-MYC. HGPS ﬁ  broblasts 
express progerin and have altered nuclear morphology, 
reduced proliferation, and loss of heterochromatin markers, 
relative to their normal counterparts. Interestingly, iPSCs 
could be generated from early-passage, but not late-
passage, HGPS ﬁ  broblasts [9] and were generated with 
less eﬃ     ciency from HGPS ﬁ   broblasts compared with 
normal ﬁ  broblasts [10], suggesting that progerin-positive 
ﬁ   bro  blasts from normal, aged individuals may pose a 
challenge to dediﬀ  erentiation.  Th  e HGPS iPSCs lost 
expression of progerin and had morphology, prolifera-
tion, and hetero  chromatic markers similar to those of 
Figure 1. Dediff  erentiation of fi  broblasts into pluripotent stem cells rescues senescence phenotypes of Hutchinson-Gilford progeria 
syndrome (HGPS) human cells. Normal (in blue) human fi  broblasts can be dediff  erentiated into induced pluripotent stem cells (iPSCs) by 
transduction with retroviruses encoding the transcription factors OCT4, SOX2, and c-MYC plus the transcriptional regulator KLF4. iPSCs can be 
expanded while maintaining their pluripotent state (passage 50×) or can be induced to diff  erentiate into fi  ve diff  erent lineages, including smooth 
muscle cells (SMCs). Fibroblasts from HGPS patients (in orange) express increased levels of progerin and have numerous senescence phenotypes 
(decreased proliferation, abnormal nuclear morphology, and altered expression of heterochromatin markers) in comparison with normal fi  broblasts. 
Conversion of these cells to iPSCs attenuates expression of progerin and senescence phenotypes so that HGPS iPSCs can be serially passaged and 
remain pluripotent. However, when induced to diff  erentiate into SMCs, these iPSCs re-express progerin and undergo premature senescence. If 
progerin expression is knocked down in the HGPS iPSC-derived SMCs, senescence is again attenuated. Conversely, ectopic expression of progerin in 
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with HGPS are lost in pluripotent iPSCs.
However, upon diﬀ   erentiation of the HGPS iPSCs 
toward embryoid bodies, progerin was again upregulated. 
Diﬀ  erentiation of the HGPS iPSCs toward smooth muscle 
cells (SMCs) resulted in altered nuclear morphology, loss 
of certain heterochromatic markers, and premature 
senes  cence. Knockdown of progerin in HGPS iPSCs by 
using short hairpin RNA (shRNA) attenuated replicative 
senescence. In contrast, expression of progerin in primary 
human SMCs induced nuclear abnormalities while 
attenuating proliferation. Th   ese data strongly support the 
conclusion that progerin is directly respon  sible for the 
cellular senescence phenotypes associated with HGPS. 
Furthermore, this demonstrates the utility of iPSCs for 
discriminating between factors that drive a speciﬁ  c 
phenotype (in this case, cell senescence and accelerated 
aging) as compared with being a passive biomarker or 
consequence of change.
Zhang and colleagues [10] examined the diﬀ  erentiation 
capacity of HGPS iPSCs in detail, conﬁ  rming the multi-
potency of these cells. MSCs and vascular smooth muscle 
cells (VSMCs) derived from HGPS iPSCs are sensitive to 
stress such as substratum deprivation, serum starvation, 
electrical stimulation, and hypoxia. Moreover, in contrast 
to normal MSCs, MSCs derived from the HGPS iPSCs 
are unable to repair ischemic muscle damage caused by 
ligation of the femoral artery. Interestingly, neural-
derived progenitor cells derived from HGPS iPSCs 
expressed a lower level of progerin in comparison with 
VSMCs and MSCs. Th  is is consistent with the lack of 
neurodegeneration in patients with HGPS and the fact 
that most symptoms in HGPS are related to defects in 
tissues of mesenchymal origin.
Th   ese bodies of work illustrate the utility of iPSCs for 
identifying mechanisms of pathology caused by inherited 
mutations because of the potentially reversible expression 
of mutant protein in diﬀ  erentiated and dediﬀ  erentiated 
cells. In this case, the authors demonstrate that the 
mutant form of lamin A, progerin, drives senescence of 
diﬀ   erentiated, but not pluripotent, cells in HGPS. In 
addition, HGPS iPSCs oﬀ  er a unique reagent for charac-
terization of the eﬀ  ects of progerin on cellular diﬀ  erentia-
tion, nuclear morphology, epigenetic regulation of gene 
expression, genomic instability, stem cell function, and 
cellular senescence. Th   is is applicable not only to patients 
with HGPS but also to normal, older individuals.
Indeed, the HGPS iPSCs have already been used to 
provide insight into diﬀ  erences in expression of progerin 
between cell lineages and response of cells to stress. Th  e 
HGPS iPSCs can also be used to identify therapies that 
aﬀ  ect the expression, splicing, farnesylation, and function 
of progerin or to correct nuclear lamina ﬂ  uidity  by 
screening for drugs that correct diﬀ  erentiation defects. 
Correction of the HGPS mutation by homologous 
recombination or knockdown of the dominant progerin 
by using shRNA could give rise to progenitor cell popu-
lations able to treat some of the pathologies associated 
with HGPS. Importantly, given the possible role of 
progerin in natural aging, the development of strategies 
to reduce the level or activity of progerin could be applied 
to treating degenera  tion associated with aging in the 
general population.
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